Johnson & Johnson is investing $2 billion to expand a North Carolina manufacturing facility, part of a broader initiative to bring biopharmaceutical manufacturing onshore. The company will create approximately 120 new jobs in the state over a 10-year period.
The investment follows President Donald Trump’s tariff policies aimed at boosting domestic manufacturing across multiple industries. Johnson & Johnson CEO Joaquin Duato said, “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.”
The company has announced a $55 billion investment in US manufacturing, research and development, and technology over the next four years. Several companies, including Eli Lilly and Apple, have also made similar investments in recent months.
Economist Michael Szanto believes that reshoring manufacturing is a “worthy goal,” but it will take time and may involve short-term pain. He notes that the US lacks skilled workers to build and staff factories, which could drive up prices. However, he emphasizes that automation and robotics will help address labor shortages in the future.
Johnson & Johnson’s investment comes as the company aims to share plans for additional advanced manufacturing facilities in the US and expand its current sites. The move highlights the company’s commitment to ensuring a significant portion of its medicines are manufactured domestically.
Source: https://www.foxbusiness.com/lifestyle/johnson-johnson-investing-2b-us-manufacturing-creating-new-jobs